Abstract Development and Phase 3 testing of the most advanced malaria vaccine, RTS,
S/AS01, indicates that malaria vaccine R&D is moving into a new phase. Field trials of …

Early data emerging from the first phase 3 trial of a malaria vaccine are raising hopes that a
licensed vaccine will soon be available for use in endemic countries, but given the relatively …

Induction of antigen-specific CD8+ T cells offers the prospect of immunization against many
infectious diseases, but no subunit vaccine has induced CD8+ T cells that correlate with …

The timelines for developing vaccines against infectious diseases are lengthy, and often
vaccines that reach the stage of large phase 3 field trials fail to provide the desired level of …

Controlled human malaria infection (CHMI) entails deliberate infection with malaria
parasites either by mosquito bite or by direct injection of sporozoites or parasitized …

There is an urgent need to develop new tuberculosis (TB) vaccines to safely and effectively
boost Bacille Calmette-Guérin (BCG)–triggered T cell immunity in humans. AdHu5Ag85A is …

Introduction Malaria, a devastating febrile illness caused by protozoan parasites, sickened
247,000,000 people in 2021 and killed 619,000, mostly children and pregnant women in …

Treatment of chronic hepatitis B (CHB) typically requires life-long administration of drugs.
Cohort and pre-clinical studies have established the link between a functional T-cell …

Background Traditionally, vaccine development against the blood-stage of Plasmodium
falciparum infection has focused on recombinant protein-adjuvant formulations in order to …

Background Gene-based vaccination using prime/boost regimens protects animals and
humans against malaria, inducing cell-mediated responses that in animal models target liver …